Please login to the form below

Not currently logged in
Email:
Password:

Lusduna

This page shows the latest Lusduna news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Merck & Co's Lantus biosimilar

CHMP recommends Merck & Co's Lantus biosimilar

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lusduna (insulin glargine) for the treatment of diabetes mellitus, after it showed comparable quality, safety and ... Lusduna is now one step closer to European

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐on biologic. Termination

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics